Koss Olinger Consulting, LLC Editas Medicine, Inc. Transaction History
Koss Olinger Consulting, LLC
- $1.2 Billion
- Q2 2025
A detailed history of Koss Olinger Consulting, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Koss Olinger Consulting, LLC holds 10,000 shares of EDIT stock, worth $24,900. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$24,900
Previous $11,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding EDIT
# of Institutions
226Shares Held
48.2MCall Options Held
436KPut Options Held
324K-
Black Rock Inc. New York, NY7.78MShares$19.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.47MShares$18.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$6.62 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL2.6MShares$6.47 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$4.89 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $171M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...